Skip to content
Peptigraph home

ARA-290 Dosage: Doses Studied, Units and Chart

What doses of ARA-290 have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureEPO-derived peptideUpdated
Doses studied
9 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
~2 min
plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of ARA-290 used in published studies
DoseFrequency and routeStudy typeSource
1, 4 or 8 mg/day (cibinetide = ARA 290)28 daysHuman RCTn = 64Investigative ophthalmology & visual science 2017, PMID 28475703
4 mgdaily · subcutaneous, self-administered · 28 days, followed for an additional monthHuman controlled trialMolecular medicine 2015, PMID 25387363
2 mgsingle doseHuman RCTn = 36European neuropsychopharmacology 2015, PMID 26431906
2 mg (n = 12) vs placebo (n = 10)three times weekly · intravenous · 4 weeksHuman RCTn = 22Molecular medicine 2012, PMID 23168581
4 mg/daysubcutaneous, self-administered · 12 weeksHuman uncontrolled trialn = 9Journal of clinical medicine 2020, PMID 32674280
30ug/kgdaily · subcutaneousAnimal · mouse (genetic diabetes, db/db) (not a human result)Biochimica et biophysica acta. Molecular basis of disease 2018, PMID 29223734
35, 70 ug/kgonce daily · intraperitonealAnimal · rat (not a human result)Journal of neuroimmunology 2014, PMID 24518674
30 or 120 ug/kgdaily · intraperitonealAnimal · rat (not a human result)Neuroscience 2013, PMID 23262243
30 ug/kgfive doses at 2-day intervals then once per week · intraperitonealAnimal · rat and mouse (including beta-common receptor knockout mice) (not a human result)n = 8Anesthesiology 2011, PMID 21873879

Before anyone considers it

  • ARA-290 is not FDA approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Doses and routes across the human trials

In sarcoidosis-related small fiber neuropathy, a 2 mg intravenous dose was given three times weekly for 4 weeks, against placebo.[6]

A phase 2b trial compared 1, 4 and 8 mg/day with placebo.[3]

In the phase 2b trial, the placebo-corrected mean change in corneal nerve fiber area at day 28 was 109 (1 mg), 697 (4 mg; P = 0.012) and 431 (8 mg); only the 4 mg confidence interval excluded zero.[3]

A diabetic macular edema trial had patients self-administer cibinetide 4 mg/day subcutaneously for 12 weeks.[7]

Regulatory

Drugs@FDA returned no ARA-290 match, so no label sets a regimen.[13]

Common questions

Is ARA-290 FDA approved?

No. ARA-290 is not FDA approved for any use.

What is the ARA 290 dose?

Trial amounts included 1, 4 and 8 mg/day arms; none is a recommendation.[3]

Is there an ARA 290 dosage chart or cycle?

No chart or cycle has a regulator source; the human trials ran for a few weeks.[13]

More on ARA-290

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
  4. 4ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
  5. 5Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
  6. 6Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
  7. 7A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020PMID 32674280Accessed 2 Oct 2026
  8. 8Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease · 2018PMID 29223734Accessed 2 Oct 2026
  9. 9Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.Journal of neuroimmunology · 2014PMID 24518674Accessed 2 Oct 2026
  10. 10The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model.Neuroscience · 2013PMID 23262243Accessed 2 Oct 2026
  11. 11ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
  12. 12Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
  13. 13Drugs@FDA (openFDA) search: active ingredient "ARA-290"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.